Skip to content

    Breast Cancer Health Center

    Font Size

    FDA Moves to Pull Avastin Breast Cancer Approval

    Roche/Genentech Will Fight Avastin/Breast Cancer Decision at FDA Hearing
    WebMD Health News
    Reviewed by Louise Chang, MD

    Dec. 16, 2010 - The FDA today moved to withdraw its approval of Avastin for the treatment of metastatic breast cancer.

    Avastin maker Genentech (owned by Roche) will ask the FDA to reconsider at a formal public hearing. Until then -- or until FDA rejects the hearing request -- Avastin will continue to be FDA approved for breast cancer.

    Today's action does not affect Avastin's approval for treatment of advanced colon, lung, kidney, and brain cancers.

    "I understand the FDA decision is disappointing for patients with breast cancer. It is disappointing for the FDA as well," Richard Pazdur, MD, director of the FDA's oncology drug office, said at a news teleconference.

    "We believe women living in the United States with metastatic HER2-negative breast cancer should also have Avastin as a treatment option, and, therefore, we will request a hearing with the FDA," Hal Barron, MD, chief medical officer and head of global product development for Genentech, said in a news release.

    In a 12-1 vote last July, an expert advisory panel urged the FDA to withdraw Avastin's approval for breast cancer. The panel found that the drug's risks outweigh any benefit it might have for breast cancer patients.

    Avastin Breast-Cancer Approval: FDA, European Medicines Agency Differ

    The FDA's earlier approval was based on a clinical trial in which Avastin in combination with a common form of chemotherapy (paclitaxel) delayed the growth of metastatic breast cancer by 5.5 months. However, the trial was stopped early and no significant effect on overall survival was seen.

    That was enough for the European Medicines Agency, the European Union's version of the FDA. The EMA granted full approval to Avastin for breast cancer treatment in combination with paclitaxel.

    The FDA took a different approach. In 2008 -- against the advice of an earlier expert panel -- it granted only a conditional, expedited form of approval for Avastin's use in breast cancer. To get full FDA approval, Genentech was required to submit additional clinical trial data showing that the drug could extend overall survival. The typical patient with metastatic breast cancer survives 18 to 24 months after diagnosis.

    Three new studies submitted to the FDA by Genentech not only failed to show an improvement of overall survival, but also failed to show that Avastin could delay tumor progression was well as it had in the first trial.

    Today on WebMD

    Breast Cancer Overview
    From mammograms to living after treatment.
    Dealing with breast cancer
    Get answers to your questions.
    woman having mammogram
    The 3 latest tips to know.
    woman undergoing breast cancer test
    Most abnormalities aren’t breast cancer.
    Resolved To Quit Smoking
    Breast Cancer Treatments Improving
    Woman getting mammogram
    Screening Tests for Women
    serious woman
    Pink badge on woman chest to support breat cancer
    what is your cancer risk
    breast cancer survivors